CD41 antibody | MWReg30
Rat anti Mouse CD41 antibody, clone MWReg30 (MCA2245) used for the evaluation of CD41 expressing megakaryocyte precursor numbers in murine haematopoietic organs by flow cytometry.
Image caption:
SHIP deficient mice have increased number of functional MKP in hematopoietic organs.
(A) BM, spleen, and PB MKP phenotype in SHIP−/− (−/−) and SHIPΔIP/ΔIP (ΔIP/ΔIP) mice. Shown are representative flow cytometry dot plots of CD41 (x-axis) versus c-Kit (y-axis) after gating on live and Lin− cells. MKP (Lin−c-Kit+CD41+) are represented in the right upper quadrants and MK (Lin−c-Kit−CD41+) are represented in the right lower quadrants. Percentages for each population are indicated on each plot. (B) Represented are the mean±standard error mean (SEM) (n = 4 for experimental groups WT C57Bl6 and SHIP−/−, while n = 6 for experimental groups WT 129SvJ and SHIPΔIP/ΔIP) of the absolute numbers of MKP in BM, spleen and PB of SHIP deficient mice (black columns) compared to respective WT littermates (gray columns). Mice strains specified in the graphs. (C) Represented is the mean±SEM (n = 4 for experimental groups WT C57Bl6 and SHIP−/−, while n = 6 for experimental groups WT 129SvJ and SHIPΔIP/ΔIP) of total body MKP numbers determined as the calculated sum of MKP in one whole spleen plus MKP in one femur ×16.6 (since one femur is estimated to contained 6% the total marrow) [3]. (D) Represented is the mean±SEM of CFU-MK colonies in BM and spleen of SHIP−/− (n = 7) and WT (n = 7) littermates. Statistical analysis was established using the Mann-Whitney test. p values indicated on each graph.
From: Perez LE, Desponts C, Parquet N, Kerr WG (2008)
SH2-Inositol Phosphatase 1 Negatively Influences Early Megakaryocyte Progenitors.
PLoS ONE 3(10): e3565.
This image is from an open access article distributed under the terms of a Creative Commons Attribution License.
Rat anti Mouse CD41 antibody, clone MWReg30 used for the demonstration of CD41 expressing megakaryocytes in murine spleen and bone marrow by immunohistochemistry on formalin fixed, paraffin embedded tissue sectons.
Image caption:
MK morphology and Glycoprotein IIB-IIIa (CD41) immunostain in BM and spleen of SHIP deficient mice.
(A). Hematoxylin-Eosin staining of BM and spleen of SHIP−/− (−/−) and wild type (WT) littermate controls. Spleen of SHIP deficient mice is characterized by a massive infiltrate with morphologically appearing MK (left panel) compared to WT littermates (right panel). BM of SHIP−/− mice contained hypolobulated micro-MK compared to hyperlobulated MK in WT BM. Magnification: ×60. Results are representative of those obtained in 3 animals per experimental group (B). Glycoprotein IIB-IIIA (CD41) immuno-histochemistry. Spleen of SHIP−/− mice contained a higher percentage of CD41+ cells compared to WT spleen. Magnification: ×40. BM of SHIP deficient mice contained comparable number of CD41+ cells compared to WT. Magnification: ×60.
From: Perez LE, Desponts C, Parquet N, Kerr WG (2008)
SH2-Inositol Phosphatase 1 Negatively Influences Early Megakaryocyte Progenitors.
PLoS ONE 3(10): e3565.
This image is from an open access article distributed under the terms of a Creative Commons Attribution License.
Rat anti Mouse CD41 antibody, clone MWReg30 (MCA2245) used to evaluate CD41 staining in mouse brain by immunohistochemistry on acetone fixed tissue cryosections.
Image caption:
Platelet aggregation and neutrophil recruitment in the brain after intracerebral injection of OVA. OVA-immunized mice or control mice received a unilateral injection of OVA into the striatum and were assessed for presence of platelets (CD41) or polymorphonuclear cells (PMN). CD41 (a–f) or PMN (g–l) immunoreactivity is shown after 1 day, 3 days or 7 days in OVA-immunized mice or non-immunized mice. As a positive control, OVA was injected in the skin of an OVA-immunized mouse and assessed for PMN recruitment (n–m). Representative data of n = 3 per treatment and time point is shown.
From: Teeling JL, Carare RO, Glennie MJ, Perry VH.
Intracerebral immune complex formation induces inflammation in the brain that depends on Fc receptor interaction.
Acta Neuropathol. 2012 Oct;124(4):479-90.
doi: 10.1007/s00401-012-0995-3.
This image is from an open access article distributed under the terms of a Creative Commons Attribution License.
FITC labeled Rat anti Mouse CD41 antibody, clone MWReg30 (MCA2245F) used for the evaluation of CD41 expression on platelet,leucocyte aggregates by flow cytometry.
Image caption:
Effect of mTPOR-MBP on platelet-leukocyte adhesion in LPS model and in the cecal ligation and puncture (CLP) model. (A) Representative flow cytometry analysis of platelet-monocyte (upper lane) and platelet-neutrophil aggregates (lower lane) detected in mice injected with saline (Control) and in mice injected with LPS treated or not with mTPOR-MBP. The two left panels show an example of monocyte (upper panel) and neutrophil (lower panel) subpopulations, identified by size and granularity in the forward scatter (FS LIN) versus side scatter (SS LIN) dot plot, using a logic gate, over the total CD45-positive leukocyte population. The others panels are representative of CD45 versus CD41 dot plots obtained in the different experimental conditions. Platelet-monocyte and platelet-neutrophil aggregates were identified, within the logic gates previously selected, as CD45 and CD41 double-positive cells. (B-C) Quantification of the percentage of platelet-monocyte (panel B) and platelet-neutrophil (panel C) aggregates detected ex vivo by flow cytometry at the indicated time-points after LPS administration, in mice treated (dashed columns) or not (black columns) with mTPOR-MBP. The number of animals studied per experimental group was as follows: Control (C) = 10; mTPOR-MBP alone = 9; LPS 3h = 8; LPS 3h + mTPOR-MBP = 6; LPS 6h = 5; LPS 6h + mTPOR-MBP = 5. (D-E) Quantification of the percentage of platelet-monocyte (panel D) and platelet-neutrophil (panel E) aggregates detected ex vivo by flow cytometry in sham-operated mice (white columns) and septic mice 18 hours after CLP, treated (dashed columns) or not (black columns) with mTPOR-MBP. The number of animals studied per experimental group was as follows: Sham-operated mice = 5; CLP = 5; CLP + mTPOR-MBP = 5. * P <0.05; ** P < 0.01; *** P <0.001.
From: Cuccurullo A, Greco E, Lupia E, De Giuli P, Bosco O, Martin-Conte E, et al. (2016)
Blockade of Thrombopoietin Reduces Organ Damage in Experimental Endotoxemia and Polymicrobial Sepsis.
PLoS ONE 11(3): e0151088.
This image is from an open access article distributed under the terms of a Creative Commons Attribution License.
Rat anti Mouse CD41:Alexa Fluor® 488
Rat anti Mouse CD41:Alexa Fluor® 647
Rat anti Mouse CD41:Biotin
Rat anti Mouse CD41:FITC
Rat anti Mouse CD41:Pacific Blue®
Rat anti Mouse CD41
Rat anti Mouse CD41:RPE
Rat anti Mouse CD41:RPE-Alexa Fluor® 647
Rat anti Mouse CD41:Alexa Fluor® 700
Rat anti Mouse CD41:Amethyst Orange
- Product Type
- Monoclonal Antibody
- Clone
- MWReg30
- Isotype
- IgG1
| Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|
| MCA2245A488 | F | 100 Tests/1ml |
|
|
| MCA2245A647 | F | 100 Tests/1ml |
|
|
| MCA2245B | F | 0.1 mg |
|
|
| MCA2245F | F | 0.1 mg |
|
|
| MCA2245PB | F | 100 Tests/1ml |
|
|
| MCA2245T | C F IP | 25 µg |
|
|
| MCA2245GA | C F IP | 0.1 mg |
|
|
| MCA2245 | C F IP | 0.25 mg |
|
|
| MCA2245PE | F | 100 Tests |
|
|
| MCA2245P647 | F | 100 Tests |
|
|
| MCA2245A700 | F | 100 Tests/1ml |
|
|
| MCA2245AMO | F | 0.1 mg |
|
Rat anti Mouse CD41 antibody, clone MWReg30 recognizes the mouse integrin alpha IIb subunit CD41. CD41 is a ~125 kDa single pass type 1 transmembrane glycoprotein expressed by platelets, megakaryocytes (Zhang et al. 2007), mast cells (Berlanga et al. 2005), and hematopoietic progenitors (Mitjavila-Garcia et al. 2002). CD41 forms a heterodimer with CD61.
The CD41/CD61 complex is important for platelet adhesion and aggregation (Patel et al. 2003) acting as a receptor for many extracellular matrix proteins including fibronectin, thrombospondin and vitronectin (Weisel et al. 1992).
Rat anti mouse CD41, clone MWReg30 has been reported to inhibit PMA induced aggregation in vitro and to induce hypothermia in vivo (Nieswandt et al. 1999).
The CD41/CD61 complex is important for platelet adhesion and aggregation (Patel et al. 2003) acting as a receptor for many extracellular matrix proteins including fibronectin, thrombospondin and vitronectin (Weisel et al. 1992).
Rat anti mouse CD41, clone MWReg30 has been reported to inhibit PMA induced aggregation in vitro and to induce hypothermia in vivo (Nieswandt et al. 1999).
Product Details
- Target Species
- Mouse
- Product Form
- Purified IgG conjugated to Alexa Fluor 488 - liquid
- Product Form
- Purified IgG conjugated to Alexa Fluor 647 - liquid
- Product Form
- Purified IgG conjugated to Biotin - liquid
- Product Form
- Purified IgG conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid
- Product Form
- Purified IgG conjugated to Pacific Blue - liquid
- Product Form
- Purified IgG - liquid
- Product Form
- Purified IgG conjugated to R. Phycoerythrin (RPE) - lyophilized
- Product Form
- Purified IgG conjugated to RPE-Alexa Fluor 647 - lyophilized
- Product Form
- Purified IgG conjugated to Alexa Fluor 700 - liquid
- Product Form
- Purified IgG conjugated to Amethyst Orange - liquid
- Reconstitution
- Reconstitute with 1 ml distilled water
- Reconstitution
- Reconstitute with 1.0 ml distilled water.
Care should be taken during reconstitution as the protein may appear as a film at the bottom of the vial. Bio-Rad recommend that the vial is gently mixed after reconstitution. - Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin - Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin - Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin - Preservative Stabilisers
0.09% Sodium Azide - Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin 5% Sucrose - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
5% Sucrose - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin - Carrier Free
- Yes
- Immunogen
- Purified murine platelets
- Approx. Protein Concentrations
- Ig concentration 0.05 mg/ml
- Approx. Protein Concentrations
- IgG concentration 0.05 mg/ml
- Approx. Protein Concentrations
- IgG concentration 0.1 mg/ml
- Approx. Protein Concentrations
- IgG concentration 0.1 mg/ml
- Approx. Protein Concentrations
- Ig concentration 0.05 mg/ml
- Approx. Protein Concentrations
- IgG concentration 1.0 mg/ml
- Approx. Protein Concentrations
- IgG concentration 0.05 mg/ml
- Approx. Protein Concentrations
- Ig concentration 0.1 mg/ml
Storage Information
- Storage
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. This product is photosensitive and should be protected from light.
Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. This product is photosensitive and should be protected from light.
Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost-free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.
Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. This product is photosensitive and should be protected from light.
Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use - Storage
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost-free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Prior to reconstitution store at +4oC. Following reconstitution store at +4oC.
DO NOT FREEZE.
This product should be stored undiluted. This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Prior to reconstitution store at +4oC.
After reconstitution store at +4oC.
DO NOT FREEZE. This product should be stored undiluted. This product is photosensitive and should be protected from light. - Storage
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. This product is photosensitive and should be protected from light.
Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use - Storage
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. This product is photosensitive and should be protected from light.
Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
More Information
- UniProt
- Q9QUM0
- Entrez Gene
- Itga2b
- GO Terms
- GO:0004872 receptor activity
- GO:0008305 integrin complex
- GO:0005925 focal adhesion
- GO:0007160 cell-matrix adhesion
- GO:0007229 integrin-mediated signaling pathway
- GO:0009897 external side of plasma membrane
- GO:0050840 extracellular matrix binding
- Acknowledgements
- This product is provided under an intellectual property licence from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchased product solely in research, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad CA 92008 USA or outlicensing@thermofisher.com
- Acknowledgements
- This product is provided under an intellectual property licence from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchased product solely in research, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad CA 92008 USA or outlicensing@thermofisher.com
- Acknowledgements
- This product is provided under an intellectual property licence from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchased product solely in research, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad CA 92008 USA or outlicensing@thermofisher.com
- Acknowledgements
- This product is provided under an intellectual property license from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchased product solely in research conducted by the buyer, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@thermofisher.com
- Acknowledgements
- This product is provided under an intellectual property licence from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchased product solely in research, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad CA 92008 USA or outlicensing@thermofisher.com
- Regulatory
- For research purposes only
Applications of CD41 antibody
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| Flow Cytometry | Neat | ||
| Flow Cytometry | Neat | ||
| Flow Cytometry | Neat | 1/10 | |
| Flow Cytometry | Neat | 1/10 | |
| Flow Cytometry | Neat | ||
| Flow Cytometry | 1/50 | 1/100 | |
| Immunohistology - Frozen | |||
| Immunoprecipitation | |||
| Flow Cytometry | Neat | ||
| Flow Cytometry | Neat | ||
| Flow Cytometry | Neat | ||
| Flow Cytometry | Neat |
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
The Fc region of monoclonal antibodies may bind non-specifically to cells expressing low affinity fc receptors. This may be reduced by using SeroBlock FcR (BUF041A/B). - Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
The Fc region of monoclonal antibodies may bind non-specifically to cells expressing low affinity fc receptors. This may be reduced by using SeroBlock FcR (BUF041A/B) - Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
The Fc region of monoclonal antibodies may bind non-specifically to cells expressing low affinity fc receptors. This may be reduced by using SeroBlock FcR (BUF041A/B). - Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
The Fc region of monoclonal antibodies may bind non-specifically to cells expressing low affinity Fc receptors. This may be reduced by using SeroBlock FcR ( BUF041A/B). - Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
The Fc region of monoclonal antibodies may bind non-specifically to cells expressing low affinity fc receptors. This may be reduced by using SeroBlock FcR (BUF041A/B). - Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
The Fc region of monoclonal antibodies may bind non-specifically to cells expressing low affinity fc receptors. This may be reduced by using SeroBlock FcR (BUF041A/B). - Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
The Fc region of monoclonal antibodies may bind non-specifically to cells expressing low affinity fc receptors. This may be reduced by using SeroBlock FcR (BUF041A/B). - Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
The Fc region of monoclonal antibodies may bind non-specifically to cells expressing low affinity fc receptors. This may be reduced by using SeroBlock FcR (BUF041A/B) - Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
The Fc region of monoclonal antibodies may bind non-specifically to cells expressing low affinity fc receptors. This may be reduced by using SeroBlock FcR (BUF041A/B).
Copyright © 2020 Bio-Rad Antibodies (formerly AbD Serotec)
Secondary Antibodies Available
| Description | Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|
| Goat anti Rat IgG:Alk. Phos. (Mouse Adsorbed) | STAR131A | C E P WB | 1 ml |
|
|
| Goat anti Rat IgG:Biotin (Mouse Adsorbed) | STAR131B | C E IF P WB | 0.5 mg |
|
|
| Rabbit F(ab')2 anti Rat IgG:Dylight®800 | STAR16D800GA | F IF WB | 0.1 mg |
|
|
| Rabbit F(ab')2 anti Rat IgG:FITC | STAR17B | F | 1 mg |
|
|
| Rabbit F(ab')2 anti Rat IgG:HRP | STAR21B | C E P RE | 1 mg |
|
|
| Goat F(ab')2 anti Rat IgG:FITC (Mouse Adsorbed) | STAR69 | F | 0.5 ml |
|
|
| Goat anti Rat IgG:Dylight®800 (Mouse Adsorbed) | STAR71D800GA | F IF WB | 0.1 mg |
|
|
| Goat anti Rat IgG:HRP (Mouse Adsorbed) | STAR72 | C E P | 0.5 mg |
|
|
| Goat F(ab')2 anti Rat IgG:RPE (Mouse Adsorbed) | STAR73 | F | 0.5 ml |
|
Useful Reagents Available
| Description | Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|
| Mouse Seroblock FcR | BUF041A | F | 0.1 mg |
|
|
| Mouse Seroblock FcR | BUF041B | F | 0.5 mg |
|
|
| Mouse Seroblock FcR | BUF041A | F | 0.1 mg |
|
|
| Mouse Seroblock FcR | BUF041B | F | 0.5 mg |
|
|
| Mouse Seroblock FcR | BUF041A | F | 0.1 mg |
|
|
| Mouse Seroblock FcR | BUF041B | F | 0.5 mg |
|
|
| Mouse Seroblock FcR | BUF041A | F | 0.1 mg |
|
|
| Mouse Seroblock FcR | BUF041B | F | 0.5 mg |
|
|
| Mouse Seroblock FcR | BUF041A | F | 0.1 mg |
|
|
| Mouse Seroblock FcR | BUF041B | F | 0.5 mg |
|
|
| Mouse Seroblock FcR | BUF041A | F | 0.1 mg |
|
|
| Mouse Seroblock FcR | BUF041B | F | 0.5 mg |
|
|
| Mouse Seroblock FcR | BUF041A | F | 0.1 mg |
|
|
| Mouse Seroblock FcR | BUF041B | F | 0.5 mg |
|
Product Specific References
Source Reference
-
Nieswandt, B. et al. (1999) Acute systemic reaction and lung alterations induced by an antiplatelet integrin gpIIb/IIIa antibody in mice.
Blood. 94 (2): 684-93.
References for CD41 antibody
-
Winter, O. et al. (2010) Megakaryocytes constitute a functional component of a plasma cell niche in the bone marrow.
Blood. 116: 1867-75. -
Tamagawa-Mineoka, R. et al. (2007) The role of platelets in leukocyte recruitment in chronic contact hypersensitivity induced by repeated elicitation.
Am J Pathol. 170: 2019-29. -
Takayama, M. et al. (2010) Genetic analysis of hierarchical regulation for Gata1 and NF-E2 p45 gene expression in megakaryopoiesis.
Mol Cell Biol. 30: 2668-80. -
Larson, M.K. and Watson, S.P. (2006) Regulation of proplatelet formation and platelet release by integrin alpha IIb beta3.
Blood. 108: 1509-14. -
Zanzinger, K. et al. (2009) Regulation of triggering receptor expressed on myeloid cells 1 expression on mouse inflammatory monocytes.
Immunology. 128: 185-95. -
Lutskiy, M.I. et al. (2007) WASP localizes to the membrane skeleton of platelets.
Br J Haematol. 139: 98-105. -
Sullivan, B.P. et al. (2010) Protective and damaging effects of platelets in acute cholestatic liver injury revealed by depletion and inhibition strategies.
Toxicol Sci. 115: 286-94. -
Fujita, R. et al. (2013) NF-E2 p45 Is Important for Establishing Normal Function of Platelets.
Mol Cell Biol. 33: 2659-70. -
Perez, L.E. et al. (2008) SH2-inositol phosphatase 1 negatively influences early megakaryocyte progenitors.
PLoS One. 3: e3565. -
Teeling, J.L. et al. (2012) Intracerebral immune complex formation induces inflammation in the brain that depends on Fc receptor interaction
Acta Neuropathol. 124: 479-90. -
Motohashi, H. et al. (2010) NF-E2 domination over Nrf2 promotes ROS accumulation and megakaryocytic maturation.
Blood. 115 (3): 677-86. -
Flierl, U. et al. (2015) Phosphorothioate backbone modifications of nucleotide-based drugs are potent platelet activators.
J Exp Med. 212 (2): 129-37. -
Devanathan, V. et al. (2015) Platelet Gi protein Gαi2 is an essential mediator of thrombo-inflammatory organ damage in mice.
Proc Natl Acad Sci U S A. 112 (20): 6491-6. -
Woods, S.J. et al. (2015) Kinetic profiling of in vivo lung cellular inflammatory responses to mechanical ventilation.
Am J Physiol Lung Cell Mol Physiol. 308 (9): L912-21. -
Goggs, R. et al. (2013) The small GTPase Rif is dispensable for platelet filopodia generation in mice.
PLoS One. 8 (1): e54663. -
Williams, C.M. et al. (2016) Identification of roles for the SNARE-associated protein, SNAP29, in mouse platelets.
Platelets. 27 (4): 286-94. -
Cuccurullo, A. et al. (2016) Blockade of Thrombopoietin Reduces Organ Damage in Experimental Endotoxemia and Polymicrobial Sepsis.
PLoS One. 11 (3): e0151088. -
Criel, M. et al. (2016) Absence of Pear1 does not affect murine platelet function in vivo.
Thromb Res. 146: 76-83. -
Ryan, J. et al. (2016) Myeloid cell-mediated renal injury in rapidly progressive glomerulonephritis depends upon spleen tyrosine kinase.
J Pathol. 238 (1): 10-20. -
Thomson, A.K. et al. (2017) Survival of motor neurone protein is required for normal postnatal development of the spleen.
J Anat. 230 (2): 337-46. -
Asai, J. et al. (2016) Platelets Regulate the Migration of Keratinocytes via Podoplanin/CLEC-2 Signaling during Cutaneous Wound Healing in Mice.
Am J Pathol. 186 (1): 101-8.
